Gender Disparities in Short-Term In-Hospital Outcomes for Patients Admitted With Sepsis

severity of their influenza symptoms over 10 days. Linear mixed-effects models were used for the primary comparisons. Results: We excluded 4214 patients and 528 declined participation. The most common exclusion was concomitant statin use.We enrolled 116 patients, 59 in the atorvastatin group and 57 in the placebo group. Groups were well-matched with regard to age, sex, race, comorbid conditions and baseline influenza symptom score (all p >0.05). There was no difference in rates of discharge from the ED, ward or ICU admission between groups (p=0.083). There was no difference observed between groups in the change in IL-6 levels (p= 0.30). However, there was a significant effect observed in IL-10 levels (p=0.044). There were significant differences in the overall influenza symptom score between groups (p=0.049) favoring faster resolution in the atorvastatin group. There were no significant differences in safety concerns identified between the groups Conclusion: Atorvastatin administration in patients with acute influenza appears safe. We found attenuation of IL-10 levels in the atorvastatin group, but not in IL-6 levels. Patients receiving atorvastatin reported improvement in their clinical symptoms at a faster rate than those in the placebo group.